We also show that IPF treatment agent pirfenidone attenuates TAC-induced arterial dilatation, inflammation and remodeling by inhibiting Smad3 activation and ERK1/2 activation, and this effect is dependent on AGGF1. The gene discussed is MAPK3; the disease is idiopathic pulmonary fibrosis.